California-based AI drug discovery company PostEra and Amgen have entered a research collaboration for a multi-target drug discovery project.
The partnership will focus on advancing up to five small molecule programs by combining PostEra's AI platform Proton and Amgen's drug discovery skillset. Amgen will also receive the option to leverage some of PostEra's AI technologies for its internal programs, apart from the ongoing collaboration.
The collaboration entails upfront and milestone payments plus royalties on any products developed through the partnership. The terms and exact details of the agreement have not been disclosed.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.